Transfer of virology and BBV diagnostic testing business
20th January 2009
iQur has decided to focus on its exciting vaccines programme, building upon promising early results to develop therapeutic and prophylactic vaccines for hepatitis, other infections and cancer. As a result, the diagnostics business of iQur has been transferred to Delphic, a provider of specialist diagnostics for HIV and hepatitis since 2001.
iQur would like to reassure its customers that all diagnostic testing services will continue to be delivered as normal, to the same high standards and without interruption.
iQur will continue to provide the ELF™ test for assessing liver fibrosis from its Southampton laboratory, in partnership with Siemens.
|
|
Partnerships in Clinical Trials
18th September 2008
iQur supports multicentre clinical research trials by delivering a bespoke diagnostic testing service, with high volume analysis of samples and a rapid turnaround. |
|
New scientific publications support ELF test
18th September 2008
Further scientific support for the efficacy of iQur's non-invasive serum marker test, ELF, will shortly be published in two high-ranking peer-reviewed journals. The two studies have focussed on different disease groups, primary biliary cirrhosis and children with non-alcoholic fatty liver disease. |
|
Free BBV training videos
11th June 2008
To support our blood borne virus screening service, on-line training videos can now be viewed and downloaded free of charge. A DVD is also available on request. Using dried blood spots and oral fluid samples to screen for hepatitis and HIV is increasingly popular, particularly among community workers, and our simple kits enable samples to be obtained successfully even by non-medically trained staff. |
|
World Hepatitis Day
19th May 2008
One in twelve people worldwide is infected with either hepatitis B or hepatitis C. That's the central message of World Hepatitis Day on Monday 19th May 2008. This is the first truly global awareness event for chronic viral hepatitis B and C. |
|
Further validation of ELF in NAFLD
1st February 2008
The effectiveness of iQur's exclusive test, ELF, as an accurate diagnostic tool continues to be validated in the clinical setting. A new study has corroborated earlier evidence of ELF’s ability to determine different stages of fibrosis in patients with non-alcoholic fatty liver disease. Detecting fibrosis in this disease group is important for ascertaining prognosis and for enabling the stratification of patients for emerging therapeutic interventions. |
|
New Director of Diagnostics appointed
11th October 2007
Brent Bartlett has joined iQur as Director of Diagnostics, adding considerable expertise in sales and marketing to the company. |
|
New non-executive directors appointed
6th October 2007 Two new non-executive directors have recently joined the Board of iQur. Experienced in business development and project management, Brenda Reynolds and Peter Woodford have been appointed to support iQur's increasing growth and future plans. |
|
Completion of successful funding round
10th September 2007
On 19th July, the Company completed its 4th, and most successful, round of funding. The round was over-subscribed and raised a total of £3.3m through an injection of new funds and conversion of obligations. |
|
iQur laboratory receives CPA accreditation
6th September 2007
iQur is proud to announce that our diagnostic laboratory is now fully accredited by Clinical Pathology Accreditation (UK) Ltd. Accreditation is only granted following a rigorous inspection process and signifies our full compliance with this nationally recognised quality management system.
Assessors commented in particular on the ‘professional and dynamic leadership, clear direction and … commitment to success.’ They concluded that our laboratory ‘provides an excellent service to users. Turnaround times were exceptionally good and the department monitored these closely. The staff were … clearly focussed on service delivery.’ |
|
iQur-led consortium awarded grant for £1.1 million project to develop combined vaccine for hepatitis A and B
7th August 2007
A consortium of companies, led by liver disease experts iQur Ltd, has been awarded a grant by the Technology Strategy Board for a £1.1 million project that will develop a novel combined vaccine for hepatitis A and B.
Research conducted by iQur over the past 12 months has suggested that a recombinant vaccine based on a genetic construct of hepatitis B antigens combined with antigens specific for hepatitis A and B will dramatically increase vaccine efficiency. The properties of this ‘tandem-core’ vaccine are such that commercial scale manufacture will require a special bio-manufacturing process to enable rapid progression into clinical trials. |
|
